Partnering is increasingly the choice for securing market share and business growth...
... Teva’s recent acquisition of Barr Pharmaceuticals may be the latest headline grabbing deal, but industry and commerce alike must have a complete understanding of the medium-sized generic drug manufacturers. The operating environment is changing rapidly as the industry matures and growth focuses on new market opportunities.
Consolidation continues to affect the market, with fewer big players dominating. Acquisition is still a favoured route to fast market access but strategic partnering is on the rise. In such a market you need to know...
But…
Who are the medium-sized companies of note?
How well do they perform?
What drugs do they produce?
Where are they located?
This report will tell you!
Additional Information
Identify merger, acquisition and partner candidates in the rapidly changing global generics market…
Consolidation and collaboration runs throughout the generic industry. Here’s just a taste of the acquisitions, controlling investments and deals in 2008/09...
Ascent to acquire Green Cross Pharma of Singapore
Aurobindo Pharma and Pfizer to commercialise off-patent products
Biocon and Mylan enter generic biologics development
Sanitas acquires Homeofarm
Hovione acquires Pfizer plant in Ireland
Adcock Ingram tried and failed to acquire Cipla Medpro
Hi-Tech Pharmacal acquires ECR Pharmaceuticals
URL Pharma acquires PharmPro manufacturing facility and equipment
Strategic partnering
In addition to outright purchase, strategic partnering or the acquisition of specific drug assets is on the rise as companies seek to bring lower costs and focus to their portfolios. With business cycles growing shorter and shorter, market entry is quicker and more reliable through acquisition and partnering.
The fundamental market drivers are sound
In addition to ongoing expansion, there are other drivers which are causing generic companies to consider the future:
Over the next 5 years over 40 blockbuster pharmaceutical products such as Lipitor, Cozaar, Effexor, Plavix, and Cymbalta will be losing patent protection.
The number of biologics coming into the remit of generic companies is increasing, raising interest in companies with biosimilars production capability.
The branded industry’s response
The branded industry continues to vigorously protect its IP and maximise the lifetime value of its products. While legal initiatives will remain a key weapon there will also be commercial responses such as issuing early branded generics, collaborative working with a limited number of generic producers, new formulations or combination products.
Identify new business opportunities and assess risk
For everyone needing to evaluate the generic industry’s competitive landscape, this thoroughly-researched and expanded 2nd edition of Partnering in the Global Generics Industry 2009: A guide to companies (published October 2009) is essential reading. In over 460 pages this new, completely revised edition references 170 generic companies operating in 40 markets around the world.
(0 items)
